Financial Survey: BioLife Solutions (NASDAQ:BLFS) & WuXi AppTec (OTCMKTS:WUXIF)

WuXi AppTec (OTCMKTS:WUXIF) and BioLife Solutions (NASDAQ:BLFS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for WuXi AppTec and BioLife Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WuXi AppTec	0	0	0	0	0.00
BioLife Solutions	1	7	1	1	2.20

BioLife Solutions has a consensus price target of $31.38, indicating a potential downside of 9.48%. Given BioLife Solutions’ stronger consensus rating and higher probable upside, analysts plainly believe BioLife Solutions is more favorable than WuXi AppTec.

Earnings & Valuation

This table compares WuXi AppTec and BioLife Solutions”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WuXi AppTec	N/A	N/A	N/A	N/A	N/A
BioLife Solutions	$96.21 million	17.60	-$4.59 million	($0.08)	-433.25

WuXi AppTec has higher earnings, but lower revenue than BioLife Solutions.

Profitability

This table compares WuXi AppTec and BioLife Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
WuXi AppTec	N/A	N/A	N/A
BioLife Solutions	53.29%	2.80%	2.57%

Insider & Institutional Ownership

93.2% of BioLife Solutions shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BioLife Solutions beats WuXi AppTec on 10 of the 10 factors compared between the two stocks.

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.